TrialAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2015

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.

Priska Kaufmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.